Skip to main content

UNC Lineberger Comprehensive Cancer Center’s Carey K. Anders, MD, and Andrew Z. Wang, MD, have been selected to participate in the 2018-2019 American Society of Clinical Oncology Leadership Development Program.

image2
UNC Lineberger’s Carey Anders, MD, and Andrew Wang, MD, have been selected to participate in the 2018-2019 American Society of Clinical Oncology Leadership Development Program.

The ASCO Leadership Development Program, initially launched in 2009, is a year-long program designed to train future leaders in medicine by providing practicing oncologists with leadership skills training, networking opportunities and mentorship from ASCO leaders.

“The skills participants acquire can accelerate their leadership success locally, nationally, and internationally as well as within ASCO and other professional organizations,” said ASCO CEO Clifford Hudis, MD, FASCO.

Anders and Wang were selected as two of 16 participants in the program based on their leadership experience and commitment to making a difference in the oncology community.

Anders is a UNC Lineberger member and co-director of UNC’s Breast Program, section leader and clinical trials director for the UNC Breast Center, and associate professor in the UNC School of Medicine Division of Hematology/Oncology. She is leading research to identify potential treatments for breast cancer that had spread to the brain, as well as to understand the genetic basis for breast cancer metastasis.

Wang is a UNC Lineberger member, an associate professor and the director of clinical and translational research for the UNC School of Medicine Department of Radiation Oncology. He is also co-director of the Carolina Cancer Nanotechnology T32 Training Program. His research is focused on using nanomedicine to improve cancer drug delivery and treatment outcomes. He has also applied biomedical engineering approaches to clinical science to develop new potential models of cancer metastasis.